The stock of Pediapharm Inc (CVE:PDP) is a huge mover today! About 77,500 shares traded hands or 23.80% up from the average. Pediapharm Inc (CVE:PDP) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
The move comes after 5 months positive chart setup for the $19.27M company. It was reported on Nov, 28 by Barchart.com. We have $0.28 PT which if reached, will make CVE:PDP worth $963,500 more.
More notable recent Pediapharm Inc (CVE:PDP) news were published by: Midasletter.com which released: “PediaPharm Inc. CEO Sylvain Chretien on Roche Holding, Senvest Capital, Knight …” on April 28, 2015, also Marketwired.com with their article: “Pediapharm Announces Second Quarter Financial Results-Revenue More Than …” published on November 28, 2016, Marketwired.com published: “Pediapharm Receives Health Canada Approval for Rupatadine” on July 21, 2016. More interesting news about Pediapharm Inc (CVE:PDP) were released by: Marketwired.com and their article: “Knight Acquires Minor Stake in Pediapharm” published on July 15, 2016 as well as Marketwired.com‘s news article titled: “Pediapharm Announces Global Exclusive Licensing Agreement for Relaxa(R), an …” with publication date: September 19, 2016.
Pediapharm Inc. is a specialty pharmaceutical company. The company has a market cap of $19.27 million. The Firm distributes prescription medicines used to treat pathological conditions that mainly affect children from infancy to 18 years of age. It has a 26.16 P/E ratio. The Firm sells products and offers marketing services to the pharmaceutical industry, particularly related to pediatric care.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.